Loss of Betaglycan Expression in Ovarian Cancer: Role in Motility and Invasion
Open Access
- 1 June 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (11), 5231-5238
- https://doi.org/10.1158/0008-5472.can-07-0035
Abstract
The transforming growth factor-β (TGF-β) superfamily members, TGF-β, activin, and inhibin, all have prominent roles in regulating normal ovarian function. Betaglycan, or the type III TGF-β receptor, is a coreceptor that regulates TGF-β, activin, and inhibin signaling. Here, we show that betaglycan expression is frequently decreased or lost in epithelial derived ovarian cancer at both the mRNA and protein level, with the degree of loss correlating with tumor grade. Treatment of ovarian cancer cell lines with the methyltransferase inhibitor 5-aza-2-deoxycytidine and the histone deacetylase inhibitor trichostatin A resulted in significant synergistic induction of betaglycan message levels and increased betaglycan protein expression, indicating that epigenetic silencing may play a role in the loss of betaglycan expression observed in ovarian cancer. Although restoring betaglycan expression in Ovca429 ovarian cancer cells is not sufficient to restore TGF-β–mediated inhibition of proliferation, betaglycan significantly inhibits ovarian cancer cell motility and invasiveness. Furthermore, betaglycan specifically enhances the antimigratory effects of inhibin and the ability of inhibin to repress matrix metalloproteinase levels in these cells. These results show, for the first time, epigenetic regulation of betaglycan expression in ovarian cancer, and a novel role for betaglycan in regulating ovarian cancer motility and invasiveness. [Cancer Res 2007;67(11):5231–8]Keywords
Other Versions
This publication has 41 references indexed in Scilit:
- The type III TGF-β receptor suppresses breast cancer progressionJCI Insight, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Betaglycan induces TGF-β signaling in a ligand-independent manner, through activation of the p38 pathwayCellular Signalling, 2006
- BRCA1 promoter methylation predicts adverse ovarian cancer prognosisGynecologic Oncology, 2006
- Gelatinase-mediated migration and invasion of cancer cellsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2005
- Origins and molecular pathology of ovarian cancerLaboratory Investigation, 2005
- A Novel Mechanism for Regulating Transforming Growth Factor β (TGF-β) SignalingJournal of Biological Chemistry, 2001
- Functional Roles for the Cytoplasmic Domain of the Type III Transforming Growth Factor β Receptor in Regulating Transforming Growth Factor β SignalingPublished by Elsevier BV ,2001
- Altered expression of transforming growth factor-? ligands and receptors in primary and recurrent ovarian carcinomaCancer, 1999
- Expression and activity of MMPS and their regulators in ovarian cancerInternational Journal of Cancer, 1994